Cftr Trikafta denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Trikafta (Elexacaftor/Tezacaftor/Ivacaftor) on Medical-Necessity Grounds

Blue Cross Blue Shield plans routinely require treating physicians to demonstrate that a CFTR modulator combination therapy is the appropriate choice for a specific patient's confirmed CFTR mutation genotype and clinical status. A medical-necessity denial typically means the plan's medical reviewer concluded that the submitted documentation did not clearly establish that the patient meets the criteria outlined in BCBS's coverage policy for this drug class. This is highly appealable — the clinical evidence base for this therapy is robust and well-recognized by cystic fibrosis specialty organizations.

## Your Federal Appeal Rights

Under ACA §2719, non-grandfathered plans must offer at least one internal appeal and access to independent external review. Under ERISA §503, employer-sponsored plans must provide a full-and-fair review. You generally have 180 days from the denial notice to file an internal appeal. If the internal appeal is denied, you may request external review through an independent review organization (IRO) — typically within four months of that denial. For urgent or time-sensitive situations, an expedited review (often resolved within 72 hours) is available when waiting for the standard timeline would seriously jeopardize health.

## The Concrete Appeal Process

1. Request the denial letter and plan's coverage policy — the denial must cite the specific criteria the plan applied. Obtain BCBS's current published medical policy for CFTR modulators. 2. File a written internal appeal within the deadline stated on the denial letter. 3. If denied internally, request independent external review in writing. 4. A pediatric or adult CF specialist's involvement strengthens every level of appeal.

## Documentation to Gather

• Confirmed CFTR genotype report from a certified genetics laboratory, showing both mutations
• Pulmonary function test history with trend data showing disease trajectory
• Comprehensive clinical notes documenting symptom burden, exacerbation frequency, hospitalizations, and functional status
• Prior treatment history with dates and documented outcomes for any therapies previously used
• Prescriber's medical-necessity letter explaining why this specific modulator combination is indicated for this patient's genotype and clinical picture, referencing the FDA-approved prescribing information and applicable Cystic Fibrosis Foundation guidelines

## Criteria-Mapping Structure

Request the full text of BCBS's coverage criteria. Then build a side-by-side table:

| Plan Requirement | Supporting Chart Documentation | |---|---| | Confirmed eligible CFTR genotype | Genetics lab report (date, lab name, result) | | Age/weight eligibility per FDA label | Chart entry confirming patient meets FDA-approved indication | | Prescriber is CF specialist or coordinating with one | Referring/treating provider credentials | | Prior therapies tried (if required) | Medication history with start/stop dates and response notes |

Copy every criterion from both the FDA prescribing label and the BCBS medical policy verbatim, then answer each with a specific chart fact. Gaps in this mapping are the most common reason second-level appeals also fail — close every gap before submitting.